Neoantigen treatment prioritization using multivariate analysis based on: HLA genotype, self-similarity, similarity to known antigens, antigen expression levels and mutant allele frequency
US10563266B2 · kind B2 · utility
2Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 14, 2016 |
| Grant date | Feb 18, 2020 |
| Priority date | — |
| Expiry date | Jun 2, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70539
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Cancer immunology provides promising new avenues for cancer treatment but validation of potential neoantigens to target is costly and expensive. Analysis of MHC binding affinity, antigen processing, similarity to known antigens, predicted expression levels (as mRNA or proteins), self-similarity, and mutant allele frequency, provides screening method to identify and prioritize candidate neoantigens using sequencing data. Methods of the invention thereby save time and money by identifying the priority candidate neoantigens for further experimental validation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.